8-K: Senseonics Announces Business Update and Full Year 2024 Financial Outlook

Senseonics reaffirms first half 2024 revenue, reports significant new patient growth, and provides full year 2024 financial outlook.

Summary

• Senseonics has announced its business updates and financial outlook for the full year 2024.
• The company expects global net revenue for the first half of 2024 to be $10 million, a 21% increase compared to the same period in 2023.
• New patient starts in the US have increased by over 200% in the first half of 2024 compared to the first half of 2023.
• The FDA review for the next-generation 365-day Eversense system is progressing as planned, with a launch targeted for the fourth quarter of 2024.
• Senseonics has initiated provider training and patient identification with Mercy Health, with first insertions targeted for the third quarter of 2024 and acceleration planned for the fourth quarter.
• The company anticipates full year 2024 global net revenue to be between $22 million and $24 million.
• This outlook assumes more than doubling U.S. new patient starts and a 50% increase in the global installed base compared to 2023.
• Inventory dynamics related to the 365-day product launch are expected to impact third-quarter sales, with sales expected to accelerate in the fourth quarter.
• Cash utilization for 2024 is expected to be approximately $70 million, consistent with 2023.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong growth metrics and a clear path forward, but also acknowledges some risks and challenges. The sentiment is generally optimistic but tempered by the inherent uncertainties in the medical technology sector.

Positives

• Senseonics is experiencing strong growth in new patient starts, particularly in the US market.
• The company is on track with the FDA review process for its 365-day Eversense system.
• The collaboration with Mercy Health is progressing ahead of schedule.
• The company is projecting significant revenue growth for the full year 2024.
• The global installed base is expected to increase by approximately 50% in 2024.

Negatives

• Inventory dynamics related to the 365-day product launch are expected to negatively impact third-quarter product sales.
• The company's cash utilization is expected to remain consistent with 2023 at approximately $70 million.

Risks

• The company faces uncertainties in the execution of its commercialization partnership with Ascensia Diabetes Care.
• There are uncertainties in insurer, regulatory, and administrative processes and decisions.
• The development and registration of new technology and solutions carry inherent uncertainties.
• Finalizing integration and commercial terms with new partners and third parties presents potential risks.
• The ongoing commercialization of the Eversense product and expansion of the RPM solution are subject to uncertainties.
• The current economic environment could impact the company's performance.

Future Outlook

Senseonics anticipates significant growth in 2024, driven by the launch of the 365-day Eversense system, the Mercy Health collaboration, and increased patient starts. The company expects sales to accelerate in the fourth quarter of 2024.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that the company has been executing its business plan in the first half of 2024.
• He also noted that the Eversense platform is in its strongest position of all time.
• Management believes the 365-day product and the Mercy collaboration present opportunities for transformative growth.

Industry Context

This announcement reflects the ongoing competition in the continuous glucose monitoring market, with Senseonics focusing on long-term implantable solutions. The collaboration with Mercy Health indicates a move towards integrating CGM technology into larger healthcare systems.

Comparison to Industry Standards

• Senseonics' focus on long-term implantable CGM systems differentiates it from competitors like Dexcom and Abbott, which primarily offer shorter-term wearable sensors.
• The 200% increase in new patient starts in the US is a strong indicator of market adoption, although it is important to compare this to the overall market growth rate for CGM devices.
• The projected revenue of $22-24 million for 2024 is relatively small compared to the revenue of larger players in the CGM market, but the growth rate is significant.
• The collaboration with Mercy Health is a unique approach that could provide a competitive advantage if successful, as it integrates the technology directly into a healthcare system.

Stakeholder Impact

• Shareholders can expect potential growth in revenue and market share.
• Patients with diabetes may benefit from the long-term implantable CGM technology.
• Healthcare providers will have access to a new tool for managing diabetes.
• Employees may experience growth opportunities within the company.

Next Steps

• The company will continue to advance the FDA review of the 365-day Eversense system.
• Senseonics will proceed with provider training and patient identification with Mercy Health.
• The company will focus on the commercial launch of the 365-day product in the fourth quarter of 2024.
• Senseonics will host a business update and analyst event on June 23, 2024.

Key Dates

Keywords

Eversense, CGM, Continuous Glucose Monitoring, Diabetes, Senseonics, Medical Technology, Implantable Sensor, Revenue, FDA, Patient Starts, Mercy Health